N/A N=180 Oral Health Literacy and Oral Education
Retention
Primary: Changes in the Knowledge Score — 4.81; 4.86; 4.64; 7.10 units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=163 Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease
Alzheimer's Disease
Primary: Mini-mental State Examination (MMEE) — 12; 12 score — p=0.23
N/A N=81 Treatment of Osteopenia With Melatonin
Osteoporosis
Primary: Changes in Bone Mineral Density (BMD) — -0.05; -1.45 percentage of change in BMD — p=<0.05
N/A N=60 Effect of Peri-operative Supplemental Oxygen in Wound Infection After Appendectomy
Perioperative Hyperoxygenation · Wound Infection
Primary: ASEPSIS Score — 30; 30; 0; 0 participants — p=0.5
Phase 2 N=60 Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
Leukemia
Primary: Phase I: Maximum Tolerated Dose (MTD) of Sorafenib Given With Azacitidine — 400 mg/twice daily
N/A N=28 Short-term Cardiovascular Benefits of Wearing Particulate-filtering Respirators
Autonomic Nervous System Imbalance · Blood Pressure · Inflammation
Primary: Heart Rate Variability-LF Power,HF Power,VLF Power — 899.4; 838.5; 519.7; 416.6 ms^2 — p=<0.05
Phase 4 N=60 Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot & Ankle Surgery
Foot and Ankle Procedures
Primary: Postoperative Pain — 0.21; 0.05 Scores on a scale
Phase 4 N=21 Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State
Kidney Transplantation
Primary: Maximum Observed Plasma Concentration (Cmax) of Mycophenolic Acid (MPA) — 12.8; 18.7 micrograms per milliliter — p=0.0163
N/A N=185 Improving Cancer Pain Management Through Self-Care
Cancer · Pain
Primary: Average Pain Intensity Score — 1.192; 1.304 units on a scale
N/A N=103 Client Centred 'Tune-ups': do They Enhance Community Reintegration After Stroke?
Stroke
Primary: Subjective Index of Physical and Social Outcome (SIPSO) — 26.6; 26.8; 29.7; 30.1 scores on a scale — p=0.44
Phase 1 N=19 Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation
Thrombocytopenia · Acute Radiation Syndrome
Primary: Maximum Tolerated Dose (MTD) of Eltrombopag — 300 mg/day
Phase 3 N=161 Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma · Ocular Hypertension
Primary: Number of Subjects With AEs — 140 participants
Phase 2 N=32 Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study
Uterine Hemorrhage · Contraception
Primary: Cessation of Vaginal Bleeding — 37.5; 87.5 percentage of participants
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
N/A N=41 Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?
Pre Diabetes · Insulin Resistant
Primary: Quantification of Insulin Action With the Insulin Suppression Test (IST) — -3; 2 mmol/L